Eye90 (hepatocellular carcinoma technology)

2023: Technology Announcement

On May 30, 2023, the medical company ABK Biomedical announced the development of an advanced technology for the treatment of unresectable hepatocellular carcinoma, the most common primary malignant tumor of the liver.

The method is called Eye90. It involves the use of microspheres containing yttrium-90 (Y90). These tiny glass balls, smaller than a human hair in diameter, act as a radiation source to kill cancer cells. Yttrium-90 plays an important role in the treatment of liver cell carcinoma, as well as other types of neoplasms.

Innovative technology developed for the treatment of carcinoma

The peculiarity of Eye90 technology is that it is the first and only solution in the world that allows visualization during the procedure. Microspheres are radiopaque, whereby medical professionals can see the process of their delivery inside the patient's body. This increases the accuracy of targeting and makes it possible to optimally calculate the dosage. As a result, the effectiveness of the therapy as a whole is increased.

Microspheres are manufactured using a patented composition. The imaging function allows doctors to confirm the delivery of these mini capsules exactly to their destination. This approach promises a significant improvement in end results in patients with unresectable hepatocellular carcinoma.

Eye90 microspheres are a significant and highly significant technological advance in the field of radioembolic Y90 therapy that has not been seen in more than two decades - since modern therapies have become clinically available, said Andrew Kennedy, MD, chief medical officer of radiation oncology at the Sarah Cannon American Cancer Institute.[1]

Notes